Science Explorer Back to mapMap
Discussion
Hospital / health system · Chongqing · China

PEG-Bio Biopharm

pegbiocq.comROR OpenAlex
Research works
10
▲ 251% vs 2018-21
Citations
66
6.4 per fractional work
Top-10% rate
7.0%
all institutions 10.0%
Open access
33%
world 40%
International
11%
world 18%
PEG-Bio Biopharm

Not ranked overall: PEG-Bio Biopharm is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does PEG-Bio Biopharm work in?

In all years, 54% of research at PEG-Bio Biopharm is in Health Sciences, 41% in Life Sciences. Its largest fields are Medicine (54%), Biochemistry, Genetics and Molecular Biology (38%), Chemistry (5%). It does 1.6× the world's share of Health Sciences.

Health Sciences: 6 fractional works · 54.1% of its workMedicine: 6 fractional works · 54.1% of its workRadiology, Nuclear Medicine and Imaging: 2 fractional works · 14.5% of its workEndocrinology, Diabetes and Metabolism: 1 fractional works · 10.0% of its workSurgery: 1 fractional works · 7.0% of its workHematology: 1 fractional works · 6.5% of its workPediatrics, Perinatology and Child Health: 1 fractional works · 6.5% of its workPublic Health, Environmental and Occupational Health: 1 fractional works · 6.5% of its workOncology: 0 fractional works · 1.6% of its workGenetics: 0 fractional works · 0.8% of its workInfectious Diseases: 0 fractional works · 0.8% of its workLife Sciences: 4 fractional works · 40.7% of its workBiochemistry, Genetics and Molecular Biology: 4 fractional works · 37.5% of its workMolecular Biology: 3 fractional works · 33.6% of its workBiotechnology: 0 fractional works · 3.2% of its workGenetics: 0 fractional works · 0.8% of its workImmunology and Microbiology: 0 fractional works · 3.2% of its workImmunology: 0 fractional works · 3.2% of its workPhysical Sciences: 1 fractional works · 5.2% of its workChemistry: 0 fractional works · 4.8% of its workPhysical and Theoretical Chemistry: 0 fractional works · 4.8% of its workEngineering: 0 fractional works · 0.4% of its workBiomedical Engineering: 0 fractional works · 0.4% of its workALL ITS WORKPEG-Bio Biopharm10fractional works, all years
Life Sciences41%Physical Sciences5%Health Sciences54%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 5 fields, with their numbers
    1. Medicine654.1%
    1. Biochemistry, Genetics and Molecular Biology437.5%
    2. Immunology and Microbiology03.2%
    1. Chemistry04.8%
    2. Engineering00.4%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What are the most cited papers from PEG-Bio Biopharm?

The most cited paper from PEG-Bio Biopharm is "A Peptide-Based Magnetic Chemiluminescence Enzyme Immunoassay for Serological Diagnosis of Coronavirus Disease 2019" (Xue-Fei Cai et al., 2020), with 175 citations. Next come "Site‐specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity" (59) and "A Peptide-based Magnetic Chemiluminescence Enzyme Immunoassay for Serological Diagnosis of Corona Virus Disease 2019 (COVID-19)" (40).

Most cited papers
#PaperReleasedCitations
1 A Peptide-Based Magnetic Chemiluminescence Enzyme Immunoassay for Serological Diagnosis of Coronavirus Disease 2019 Xue-Fei Cai et al. · The Journal of Infectious Diseases Open access 4 May 2020 175
2 Site‐specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity Nian Gong, Ai‐Niu Ma, Lijie Zhang et al. · British Journal of Pharmacology Open access 19 Jan 2011 59
3 A Peptide-based Magnetic Chemiluminescence Enzyme Immunoassay for Serological Diagnosis of Corona Virus Disease 2019 (COVID-19) Xue-Fei Cai et al. · medRxiv PreprintOpen access 25 Feb 2020 40
4 Preparation and purification of monoclonal antibodies against chloramphenicol Yi Yu, Zhuhuan Wang, Min Li et al. · Cytotechnology Open access 10 Dec 2011 12
5 Safety, tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator PB-201 and its effects on the glucose excursion profile in drug-naïve Chinese patients with type 2 diabetes: a randomised controlled, crossover, single-centre phase 1 trial Dongyang Liu, Ying Du, Xueting Yao et al. · EClinicalMedicine Open access 5 Nov 2021 11
All 13 most cited papers, with filters and sorting

Which research topics does PEG-Bio Biopharm publish most on?

By volume in 2022-now: Glycosylation and Glycoproteins Research, Multiple Myeloma Research and Treatments, Pharmaceutical studies and practices and Acute Lymphoblastic Leukemia research.

Glycosylation and Glycop…0Glycosylation and Glycoproteins Research: 0 fractional worksMultiple Myeloma Researc…0Multiple Myeloma Research and Treatments: 0 fractional worksPharmaceutical studies a…0Pharmaceutical studies and practices: 0 fractional worksAcute Lymphoblastic Leuk…0Acute Lymphoblastic Leukemia research: 0 fractional worksPlatelet Disorders and T…0Platelet Disorders and Treatments: 0 fractional worksChildhood Cancer Survivo…0Childhood Cancer Survivors' Quality of Life: 0 fractional worksDiabetes Treatment and Management: 0 fractional worksPancreatic function and diabetes: 0 fractional worksChronic Lymphocytic Leukemia Research: 0 fractional worksHelicobacter pylori-related gastroenterology studies: 0 fractional works
Molecular BiologyHematologyPediatrics, Perinatology and Child HealthPublic Health, Environmental and Occupational Health3 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Glycosylation and Glycoproteins Research Molecular Biology 0 works
  2. 2 Multiple Myeloma Research and Treatments Hematology 0 works
  3. 3 Pharmaceutical studies and practices Pediatrics, Perinatology and Child Health 0 works
  4. 4 Acute Lymphoblastic Leukemia research Public Health, Environmental and Occupational Health 0 works
  5. 5 Platelet Disorders and Treatments Hematology 0 works
  6. 6 Childhood Cancer Survivors' Quality of Life Pediatrics, Perinatology and Child Health 0 works
  7. 7 Diabetes Treatment and Management Endocrinology, Diabetes and Metabolism 0 works
  8. 8 Pancreatic function and diabetes Surgery 0 works
  9. 9 Chronic Lymphocytic Leukemia Research Genetics 0 works
  10. 10 Helicobacter pylori-related gastroenterology studies Surgery 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available33.3%not open66.7%

World: 40% of research is openly available.

with international co-authors11.0%domestic only89.0%

World: 18% is written across borders.

How has PEG-Bio Biopharm's research output changed?

Output in 2022-2025 was 251% higher than in 2018-2021.

20152020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is PEG-Bio Biopharm as a percentage of every work published that year, 0.000014% in 2023.

0.000025%0.000050%0.000075%PEG-Bio Biopharm0.000037% in 20242020

Fractional works of PEG-Bio Biopharm over all fractional works that year. How the balance of science has shifted.

Other research institutions in Chongqing

All research institutions in Chongqing

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about PEG-Bio Biopharm. Posts are plain text and can be reported.